The hypomethylating agents decitabine and azacitidine administered at a low dose are safe and effective for patients with lower-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN), according to results of a recent study published in Blood.
Oncology Newswatch